- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BHVN
Recent news which mentions BHVN
From Motley Fool
The Week Ahead In Biotech: Gene & Cell Therapy Conference, Tapering Earnings News, OKYO Pharma IPO And More
May 16, 2022
From Benzinga
3 Dirt-Cheap Stocks You Can Buy Right Now
May 14, 2022
From Motley Fool
From Benzinga
103 Biggest Movers From Yesterday
May 11, 2022
From Benzinga
From InvestorPlace
Why Biohaven Pharmaceutical Stock Soared Today
May 10, 2022
From Motley Fool
From Benzinga
From Motley Fool
From Benzinga
From Benzinga
77 Stocks Moving In Tuesday's Mid-Day Session
May 10, 2022
From Benzinga
From Benzinga
From Benzinga
From Benzinga
From MarketWatch
From Benzinga
European Commission Granted Marketing Authorization For Pfizer and Biohaven's VYDURA® (Rimegepant) For Migraine
April 27, 2022
From Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
April 03, 2022
From Benzinga
From Benzinga
Biohaven Pharmaceutical's Return On Capital Employed Insights
February 28, 2022
Tickers
BHVN
From Benzinga
Biohaven Further Deepens Its Neurology Pipeline With Bristol Myers, Knopp Biosciences Deals
February 25, 2022
From Benzinga
The Daily Biotech Pulse: Lilly's Jardiance Gets Nod For Heart Failure, Pulmatrix Announces Reverse Split, Reata Awaits FDA Decision
February 25, 2022
From Benzinga
Earnings Scheduled For February 25, 2022
February 25, 2022
From Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
From Benzinga
Biohaven/Pfizer Partnered Rimegepant Asia-Pacific Migraine Trial Meets Primary Endpoints
February 14, 2022
From Benzinga
What to Expect From Biogen's $2.3 Billion Shopping Spree
February 12, 2022
From Motley Fool
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.